EOM Pharmaceuticals (OTCMKTS:IMUC – Get Free Report) and Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Volatility & Risk
EOM Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Valuation & Earnings
This table compares EOM Pharmaceuticals and Pliant Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
EOM Pharmaceuticals | N/A | N/A | -$1.61 million | N/A | N/A |
Pliant Therapeutics | $1.58 million | 431.73 | -$161.34 million | ($3.34) | -3.36 |
Profitability
This table compares EOM Pharmaceuticals and Pliant Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
EOM Pharmaceuticals | N/A | N/A | N/A |
Pliant Therapeutics | N/A | -48.91% | -41.09% |
Analyst Ratings
This is a summary of recent recommendations and price targets for EOM Pharmaceuticals and Pliant Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
EOM Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Pliant Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
Pliant Therapeutics has a consensus target price of $40.50, suggesting a potential upside of 261.28%. Given Pliant Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than EOM Pharmaceuticals.
Insider & Institutional Ownership
97.3% of Pliant Therapeutics shares are owned by institutional investors. 3.3% of EOM Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Pliant Therapeutics beats EOM Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About EOM Pharmaceuticals
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Receive News & Ratings for EOM Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EOM Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.